Decades of studies have provided ample evidence that glial neuroimmune activation contributes in the development of neuropathic pain. However, knowledge regarding the role of neural-glial interactions in the pathophysiology of neuropathic pain is currently lacking. In preclinical studies, calcitonin gene related peptide (CGRP), a peptide neurotransmitter, has been shown to be involved in peripheral nerve injuryinduced tactile hypersensitivity, a behavioral sign of neuropathic pain. Previously, we have also demonstrated a critical role of central nervous system (CNS) microglial CD40 in the maintenance of mechanical hypersensitivity post-peripheral nerve injury. In the current study, the possible interactions between microglial CD40 signaling and primary afferent neuron-released CGRP in regards to they affect glial cells in the spinal cord will be investigated. We hypothesize that following peripheral nerve injury, spinal cord CD40 mediates the release of CGRP from primary afferent nociceptors and this CGRP release promotes persistent pain behavior, particularly during the maintenance phase, through the induction of proinflammatory chemokine production by glia. This central hypothesis will be tested via both in vivo and in vitro studies. An established rodent neuropathic pain model, spinal nerve L5 transection (L5Tx), will be used for the in vivo studies. Dorsal root ganglia (DRG) neuron-microglia co-cultures and mixed glial cultures will be generated for the in vitro studies. The central hypothesis will be tested through 4 specific aims: 1) Examine lumbar spinal cord chemokine production following L5Tx in CD40 KO mice vs. WT mice and the role of selected chemokines in the development of behavioral hypersensitivity;2) Determine whether CGRP is involved in L5Tx-induced chemokine production and behavioral hypersensitivity;3) Evaluate the role of microglial CD40 in CGRP release by primary afferent neurons;and 4) Assess glial production of selected proinflammatory chemokines and upstream signaling pathways (mainly mitogen-activated protein kinase pathways) following CGRP stimulation in mixed glial cultures. The long-term goal of our study is to further understand the pathophysiology of nerve injury-induced neuropathic pain in order to uncover novel targets for new drug development leading to more efficacious treatments of neuropathic pain.
Neuropathic pain, defined as pain initiated or caused by a primary lesion or dysfunction in the nervous system, is one of the most devastating kinds of chronic pain and is still largely treated sub-optimally. Delineating the mechanisms leading to neuropathic pain is of crucial importance and will accelerate the design of new, more effective treatments.
|Cone, Katherine; Lanpher, Janell; Kinens, Abigail et al. (2018) Delta/mu opioid receptor interactions in operant conditioning assays of pain-depressed responding and drug-induced rate suppression: assessment of therapeutic index in male Sprague Dawley rats. Psychopharmacology (Berl) 235:1609-1618|
|Cao, Ling; Malon, Jennifer T (2018) Anti-nociceptive Role of CXCL1 in a Murine Model of Peripheral Nerve Injury-induced Neuropathic Pain. Neuroscience 372:225-236|
|Gjelsvik, Kayla Jane; Follansbee, Taylor Leon; Ganter, Geoffrey Karl (2018) Bone Morphogenetic Protein Glass Bottom Boat (BMP5/6/7/8) and its receptor Wishful Thinking (BMPRII) are required for injury-induced allodynia in Drosophila. Mol Pain 14:1744806918802703|
|McLane, Virginia D; Kumar, Saurabh; Leeming, Reno et al. (2018) Morphine-potentiated cognitive deficits correlate to suppressed hippocampal iNOS RNA expression and an absent type 1 interferon response in LP-BM5 murine AIDS. J Neuroimmunol 319:117-129|
|Davis, Seth M; Rice, Makaela; Rudlong, Jacob et al. (2018) Neonatal pain and stress disrupts later-life pavlovian fear conditioning and sensory function in rats: Evidence for a two-hit model. Dev Psychobiol 60:520-533|
|Remeniuk, Bethany; King, Tamara; Sukhtankar, Devki et al. (2018) Disease modifying actions of interleukin-6 blockade in a rat model of bone cancer pain. Pain 159:684-698|
|Govea, Rosann M; Barbe, Mary F; Bove, Geoffrey M (2017) Group IV nociceptors develop axonal chemical sensitivity during neuritis and following treatment of the sciatic nerve with vinblastine. J Neurophysiol 118:2103-2109|
|Havelin, Joshua; Imbert, Ian; Sukhtankar, Devki et al. (2017) Mediation of Movement-Induced Breakthrough Cancer Pain by IB4-Binding Nociceptors in Rats. J Neurosci 37:5111-5122|
|Lei, Wei; Mullen, Nathan; McCarthy, Sarah et al. (2017) Heat-shock protein 90 (Hsp90) promotes opioid-induced anti-nociception by an ERK mitogen-activated protein kinase (MAPK) mechanism in mouse brain. J Biol Chem 292:10414-10428|
|Follansbee, Taylor L; Gjelsvik, Kayla J; Brann, Courtney L et al. (2017) Drosophila Nociceptive Sensitization Requires BMP Signaling via the Canonical SMAD Pathway. J Neurosci 37:8524-8533|
Showing the most recent 10 out of 36 publications